The findings of the current study showed that CDH13 promoter methylation was significantly higher in bladder cancer patients than in non-tumor control samples (OR = 21.71, P < 0.001), suggesting that the methylation of CDH13 may be involved in the development of bladder cancer. This evidence concerns the gene CDH13 and urinary bladder carcinoma.